Lonza to Develop, Manufacture U.S. Biopharma Firm’s Antibody Drug Conjugate

Lonza says that biopharmaceutical company Intellect Neurosciences (New York) has awarded the future development and manufacture of the antibody-drug conjugate Conjumab-A to Lonza, subject to completion of a definitive development and manufacturing agreement. Lonza will supply the preclinical study material for the drug optimization and drug selection for Intellect’s Conjumab-A, initially focusing on age-related macular degeneration (AMD) with potential applications for Alzheimer’s disease, Lonza says. Intellect is engaged in the discovery and...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers